Bile Acids and Farnesoid X Receptor in Renal Pathophysiology.

IF 2.3 4区 医学 Q2 UROLOGY & NEPHROLOGY
Nephron Pub Date : 2024-01-01 Epub Date: 2024-02-27 DOI:10.1159/000538038
Jiufang Yang, Marco Pontoglio, Fabiola Terzi
{"title":"Bile Acids and Farnesoid X Receptor in Renal Pathophysiology.","authors":"Jiufang Yang, Marco Pontoglio, Fabiola Terzi","doi":"10.1159/000538038","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bile acids (BAs) act not only as lipids and lipid-soluble vitamin detergents but also function as signaling molecules, participating in diverse physiological processes. The identification of BA receptors in organs beyond the enterohepatic system, such as the farnesoid X receptor (FXR), has initiated inquiries into their organ-specific functions. Among these organs, the kidney prominently expresses FXR.</p><p><strong>Summary: </strong>This review provides a comprehensive overview of various BA species identified in kidneys and delves into the roles of renal apical and basolateral BA transporters. Furthermore, we explore changes in BAs and their potential implications for various renal diseases, particularly chronic kidney disease. Lastly, we center our discussion on FXR, a key BA receptor in the kidney and a potential therapeutic target for renal diseases, providing current insights into the protective mechanisms associated with FXR agonist treatments.</p><p><strong>Key messages: </strong>Despite the relatively low concentrations of BAs in the kidney, their presence is noteworthy, with rodents and humans exhibiting distinct renal BA compositions. Renal BA transporters efficiently facilitate either reabsorption into systemic circulation or excretion into the urine. However, adaptive changes in BA transporters are evident during cholestasis. Various renal diseases are accompanied by alterations in BA concentrations and FXR expression. Consequently, the activation of FXR in the kidney could be a promising target for mitigating kidney damage.</p>","PeriodicalId":18998,"journal":{"name":"Nephron","volume":" ","pages":"618-630"},"PeriodicalIF":2.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephron","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538038","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Bile acids (BAs) act not only as lipids and lipid-soluble vitamin detergents but also function as signaling molecules, participating in diverse physiological processes. The identification of BA receptors in organs beyond the enterohepatic system, such as the farnesoid X receptor (FXR), has initiated inquiries into their organ-specific functions. Among these organs, the kidney prominently expresses FXR.

Summary: This review provides a comprehensive overview of various BA species identified in kidneys and delves into the roles of renal apical and basolateral BA transporters. Furthermore, we explore changes in BAs and their potential implications for various renal diseases, particularly chronic kidney disease. Lastly, we center our discussion on FXR, a key BA receptor in the kidney and a potential therapeutic target for renal diseases, providing current insights into the protective mechanisms associated with FXR agonist treatments.

Key messages: Despite the relatively low concentrations of BAs in the kidney, their presence is noteworthy, with rodents and humans exhibiting distinct renal BA compositions. Renal BA transporters efficiently facilitate either reabsorption into systemic circulation or excretion into the urine. However, adaptive changes in BA transporters are evident during cholestasis. Various renal diseases are accompanied by alterations in BA concentrations and FXR expression. Consequently, the activation of FXR in the kidney could be a promising target for mitigating kidney damage.

肾脏病理生理学中的胆汁酸和类脂质 X 受体
背景:胆汁酸(BA)不仅是脂质和脂溶性维生素去垢剂,而且还是信号分子,参与多种生理过程。在肠肝系统以外的器官中也发现了胆汁酸受体,如类黄酮 X 受体(FXR),从而引发了对其器官特异性功能的研究。摘要:本综述全面概述了在肾脏中发现的各种 BA 种类,并深入研究了肾顶端和基底侧 BA 转运体的作用。此外,我们还探讨了各种肾脏疾病,尤其是慢性肾脏疾病(CKD)中 BA 的变化及其潜在影响。最后,我们以 FXR 为讨论中心,FXR 是肾脏中关键的 BA 受体,也是肾脏疾病的潜在治疗靶点:尽管肾脏中 BA 的浓度相对较低,但它们的存在却值得注意,啮齿动物和人类的肾脏中 BA 的组成各不相同。肾脏 BA 转运体能有效促进 BA 重吸收进入全身循环或排入尿液。然而,在胆汁淤积期,BA 转运体的适应性变化非常明显。各种肾脏疾病都伴随着 BA 浓度和 FXR 表达的改变。因此,激活肾脏中的 FXR 可能是减轻肾脏损伤的一个有前途的靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nephron
Nephron UROLOGY & NEPHROLOGY-
CiteScore
5.00
自引率
0.00%
发文量
80
期刊介绍: ''Nephron'' comprises three sections, which are each under the editorship of internationally recognized leaders and served by specialized Associate Editors. Apart from high-quality original research, ''Nephron'' publishes invited reviews/minireviews on up-to-date topics. Papers undergo an innovative and transparent peer review process encompassing a Presentation Report which assesses and summarizes the presentation of the paper in an unbiased and standardized way.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信